The prevalence of Mycoplasma pneumoniae infection in patients with ventilator-associated pneumonia hospitalized in intensive care unit

Authors

  • Fateh, Abolfazl Department of Mycobacteriology and Pulmonary Research, Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran, Iran
  • Mafi, Shirin Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
  • Rahimi Jamnani, Fatemeh Department of Mycobacteriology and Pulmonary Research, Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran, Iran
  • Sakhaee, Fatemeh Department of Mycobacteriology and Pulmonary Research, Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran, Iran
  • Siadat, Seyed Davar Department of Mycobacteriology and Pulmonary Research, Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran, Iran
  • Vaziri, Farzam Department of Mycobacteriology and Pulmonary Research, Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran, Iran
  • Zarei, Masoud Molecular Laboratory of Erfan Niyayesh Hospital, Tehran, Iran
  • Zargar, Mohsen Faculty of Science, Qom Branch, Islamic Azad University, Qom, Iran
Abstract:

Background: Ventilator-associated pneumonia (VAP) is a type of hospital acquired pneumonia with the mortality rate between 27% and 76% that develops more than 48–72 h after endotracheal intubation. Possible causes leading to this infection can be Mycoplasma pneumoniae. The objective of this study was to determine the presence of Mycoplasma pneumoniae in bronchoalveolar samples of patients with VAP who admitted in the intensive care unit (ICU). Materials and methods: In this cross-sectional study, 103 bronchoalveolar lavage samples were collected from VAP patients who admitted to ICU in Loghman, Erfan Niyayesh and Erfan Hospitals. Then, samples were investigated for presence of Mycoplasma pneumoniae using nested-PCR method with 16S rRNA gene. Results: 4 (3.9%) patients were positive for Mycoplasma pneumoniae. There was a significant relationship between the positive infectious agents with clinical signs (P=0.017) and the duration of using ventilator (P=0.043). Conclusion: The results of this study, as a first study in Iran, showed that Mycoplasma pneumoniae can be considered as true pathogens of the respiratory tract in patients with VAP and should be given more attention. To confirm the results of this study, further research is needed to reveal the association of this bacterium with VAP

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Does Re-intubation Increased Risk of Ventilator- Associated Pneumonia (VAP) in Pediatric Intensive Care Unit Patients?

Introduction:ventilator- associated pneumonia(VAP),as defined by the centers for disease control and prevention (CDC),is a pneumonia that occurs in a patient receiving mechanical ventilation that develops 48 hours or more after initiation of ventilation.re-intubation which occur within 72 hours of planned extubation may effect VAP incidence.the aim of this study was to determine VAP incidence i...

full text

ventilator-associated pneumonia in hospitalized newborns in a neonatal intensive care unit

background ventilator-associated pneumonia (vap) develops in mechanically ventilated patients 48 hours after putting the patients on the ventilator. vap is the second most common nosocomial infection in neonatal intensive care units (nicu). objectives the current study was conducted to determine the rate, microbiological characteristics and outcome of vap in neonates admitted in the nicu of sho...

full text

Methicillin Resistant Staphylococcus Aureus in Ventilator Associated ‎Pneumonia in Toxicological Intensive Care Unit

Background: Methicillin resistant Staphylococus Aureus (MRSA) is a cause of ‎nosocomial infections at intensive care unit (ICU), which imposes a high mortality and ‎morbidity on the health care systems.‎ The objective of this study was to evaluate the role of MRSA in patients with clinically ‎suspected ventilator associated pneumonia (VAP) in toxicological ICU admitted ‎patients.Methods: This ...

full text

real-time rt-pcr detection of hcn4 and adam8 genes in ventilator-associated pneumonia patients hospitalized in intensive care unit

introduction ventilator-associated pneumonia (vap)  is one of the most serious and  prevalence of  complication  among patients in the intensive care unit nosocomial infections, which are often recognized after detecting symptoms. to date, there has been no proper clinical and diagnostic marker for early detection of this disease. in this study, two hcn4 and adam8 genes in patients with vap wer...

full text

Strategies for the Prevention of Ventilator-associated Pneumonia in the Intensive Care Units: A Review

Ventilator-Associated Pneumonia (VAP) accounts for 80%-90% of hospital-acquired pneumonia cases in Intensive Care Units (ICUs). VAP occurs 48-72 hours after intubation, and is observed in 27%-29% of patients with endotracheal tube, and its risk increases with the increase in the duration of mechanical ventilation. In this review study, papers published from 1996-2018 were used to investigate st...

full text

does re-intubation increased risk of ventilator- associated pneumonia (vap) in pediatric intensive care unit patients?

introduction:ventilator- associated pneumonia(vap),as defined by the centers for disease control and prevention (cdc),is a pneumonia that occurs in a patient receiving mechanical ventilation that develops 48 hours or more after initiation of ventilation.re-intubation which occur within 72 hours of planned extubation may effect vap incidence.the aim of this study was to determine vap incidence i...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 29  issue 4

pages  313- 321

publication date 2019-12

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

No Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023